Jyong Biotech Ltd. (MENS) Cash Flow Statement

NASDAQ: MENSOperating cash, capex, free cash flow and buybacks.

Where MENS’s cash came from and went, 2025

December 31, 2025 · U.S. dollars
Cash from operations
−$3.0M
Capital expenditures
$0
Free cash flow
−$3.0M
Returned to shareholders
—
Change in cash
$1.1M
cash at year-end $1.2M
Shares issued: $17.8MShares issued$17.8MAcquisitions & other: $13.5MAcquisitions & other$13.5M · 76%Cash used in operations: $3.0MCash used in operations$3.0M · 17%Added to cash: $1.1MAdded to cash$1.1M · 6%Other financing, Debt repayment: $138,000Other uses$138,000 · 1%$17.8M
Cash from operations
−$3.0M
Acquisitions & other
−$13.5M
Net borrowing (repayment)
−$24,000
Shares issued
+$17.8M
Other financing
−$114,000
Change in cash
$1.1M

Drawn to scale: where the cash came from and how it was used. Hover for values.

MENS operating cash flow, capex and free cash flow

Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)

MENS cash flow trends, 2020–2025

Jyong Biotech Ltd. cash flow trends
MetricTrendThenLatestChange
Operating cash flow−$1.1M2020−$3.0M2025—
Capital expenditures$88,0002020$02025−100.0%
Free cash flow−$1.2M2020−$3.0M2025—

Change is the average annual growth (CAGR) or the difference between the first and latest year.

MENS cash flow by activity

OperatingInvestingFinancingChange in cash

MENS net income vs operating cash flow

Net incomeOperating cash flow

Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).

MENS cash flow statement

Jyong Biotech Ltd. annual cash flow statement
202520242023202220212020
Operating activities
Net income−$4.7M−$3.0M−$4.4M−$6.6M−$4.2M−$1.9M
Depreciation & amortization$100,000$120,000$127,000$123,000$122,000$110,000
Change in working capital$20.7M−$1.5M$1.1M$2.9M$1.2M$25,000
Other non-cash items−$19.2M$761,000$554,000$599,000$849,000$694,000
Cash from operating activities−$3.0M−$3.6M−$2.6M−$3.0M−$2.0M−$1.1M
Investing activities
Capital expenditures$0$0$0−$246,000−$137,000−$88,000
Investments (net)$3,000$0$95,000$1.4M−$1.3M—
Acquisitions & other investing−$13.5M—$0$246,000$137,000$819,000
Cash from investing activities−$13.5M—$95,000$1.4M−$1.3M$731,000
Financing activities
Net borrowing (repayment)−$24,000$2.2M$2.5M$3.6M−$1.3M—
Shares issued$17.8M$0$0$0$0$0
Other financing−$114,000−$213,000−$445,000−$276,000−$35,000$4.9M
Cash from financing activities$17.6M$2.0M$2.0M$3.3M−$1.4M$4.9M
Summary
Net change in cash$1.1M−$1.6M−$532,000$1.7M−$4.6M$5.2M
Cash at end of period$1.2M$101,000$1.7M$2.3M$551,000$5.2M
Free cash flow−$3.0M−$3.6M−$2.6M−$3.2M−$2.1M−$1.2M

Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.

MENS cash generation

In fiscal 2025 (ended December 31, 2025), Jyong Biotech generated -$3.0 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$3.0 million. Cash and equivalents rose by $1.1 million over the year.

Related: MENS income statement, MENS balance sheet. See the MENS stock overview for the latest quote and news.

MENS cash flow FAQ

What is Jyong Biotech's free cash flow?

Jyong Biotech's free cash flow was -$3.0 million in fiscal 2025: -$3.0 million of operating cash flow minus $0 of capital expenditures It was -$3.6 million a year earlier..

How much cash does Jyong Biotech generate from operations?

Jyong Biotech generated -$3.0 million of cash from operating activities in fiscal 2025.

Biotechnology: cash flow